Last-Resort hope: modified herpes virus plus immunotherapy for advanced melanoma

NCT ID NCT06590480

NO_LONGER_AVAILABLE Disease control Sponsor: Replimune, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access program provides a genetically modified herpes virus (vusolimogene oderparepvec) combined with the immunotherapy drug nivolumab to adults with advanced melanoma that has worsened after anti-PD-1 treatment. The goal is to offer potential benefit to patients who have few options left. Data will be collected in real-world settings to understand how the combination works outside of formal clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vusolimogene oderparepvec (a genetically modified herpes virus) plus nivolumab (an immunotherapy drug)
What this could lead to: If this treatment helps, it could offer a new option for people with advanced melanoma that has stopped responding to standard immunotherapy.
What could go wrong: This is an expanded access program, not a formal trial, so results are collected in real-world settings and may not prove effectiveness. The virus-based therapy may cause side effects like flu-like symptoms or injection site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MELANOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.